Cargando…

Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material

BACKGROUND: The role of methylation status of the thyroid stimulating hormone receptor gene (TSHr) in the discrimination of benign and malignant thyroid nodules has already been studied using paraffin blocks and cell lines. As cytological sampling plays an important role in assessment of thyroidal n...

Descripción completa

Detalles Bibliográficos
Autores principales: Kartal, Kinyas, Onder, Sevgen, Kosemehmetoglu, Kemal, Kilickap, Sadettin, Tezel, Yesim Gaye, Kaynaroglu, Volkan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628362/
https://www.ncbi.nlm.nih.gov/pubmed/26519197
http://dx.doi.org/10.1186/s12885-015-1861-1
_version_ 1782398439059881984
author Kartal, Kinyas
Onder, Sevgen
Kosemehmetoglu, Kemal
Kilickap, Sadettin
Tezel, Yesim Gaye
Kaynaroglu, Volkan
author_facet Kartal, Kinyas
Onder, Sevgen
Kosemehmetoglu, Kemal
Kilickap, Sadettin
Tezel, Yesim Gaye
Kaynaroglu, Volkan
author_sort Kartal, Kinyas
collection PubMed
description BACKGROUND: The role of methylation status of the thyroid stimulating hormone receptor gene (TSHr) in the discrimination of benign and malignant thyroid nodules has already been studied using paraffin blocks and cell lines. As cytological sampling plays an important role in assessment of thyroidal nodules, we have investigated the potential clinical use of TSHr methylation status of fine needle aspiration specimens reported according to Bethesda System. METHOD: Sixty nine patients who had both cytological and pathological diagnosis of the same nodule were selected. Four groups were composed according to cytological and pathological diagnoses: Benign (B), papillary thyroid carcinoma (PTC), atypia of unknown significance (AUS) and follicular neoplasia (FN). The latter 2 groups were further sub-classified into 2 as benign (AUS-B and FN-B) and malignant (AUS-M and FN-M) according to final pathological diagnosis. DNAs were isolated from the fine needle aspiration cytology specimens and the methylation status of TSHr promotor region was investigated by using methylation specific polymerase chain reaction. RESULTS: Overall, TSHr methylation was present in 58 % of cases; 71 % of malignant and 46 % of benign nodules. PTC group showed the highest TSHr methylation rate (87 %), followed by 61 % in AUS, 44 % in B, and 30 % in FN (p = 0.016). TSHr methylation rate was significantly higher in PTC group when compared to B (p = 0.013) and FN-B (p = 0.004) groups; but not in FN-M (p = 0.115) or AUS (p = 0.096) groups. All 9 cases of papillary thyroid carcinoma with lymph node metastasis showed TSHr methylation. Positive predictive value, negative predictive value, sensitivity and specificity of TSHr methylation in determination of malignancy were calculated as 60, 66, 71 and 54 %, respectively. CONCLUSION: The eminent ratio of TSHr methylation in well-differentiated thyroid carcinoma against benign thyroidal nodules adduced that TSHr methylation status can be utilized as a tumor marker for well-differentiated thyroid cancer; however, it has a limited value. The determination of methylation status of TSHr gene had no efficiency on decision of the malignant potential for the nodules which are cytologically classified as atypia of undetermined significance.
format Online
Article
Text
id pubmed-4628362
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46283622015-11-01 Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material Kartal, Kinyas Onder, Sevgen Kosemehmetoglu, Kemal Kilickap, Sadettin Tezel, Yesim Gaye Kaynaroglu, Volkan BMC Cancer Research Article BACKGROUND: The role of methylation status of the thyroid stimulating hormone receptor gene (TSHr) in the discrimination of benign and malignant thyroid nodules has already been studied using paraffin blocks and cell lines. As cytological sampling plays an important role in assessment of thyroidal nodules, we have investigated the potential clinical use of TSHr methylation status of fine needle aspiration specimens reported according to Bethesda System. METHOD: Sixty nine patients who had both cytological and pathological diagnosis of the same nodule were selected. Four groups were composed according to cytological and pathological diagnoses: Benign (B), papillary thyroid carcinoma (PTC), atypia of unknown significance (AUS) and follicular neoplasia (FN). The latter 2 groups were further sub-classified into 2 as benign (AUS-B and FN-B) and malignant (AUS-M and FN-M) according to final pathological diagnosis. DNAs were isolated from the fine needle aspiration cytology specimens and the methylation status of TSHr promotor region was investigated by using methylation specific polymerase chain reaction. RESULTS: Overall, TSHr methylation was present in 58 % of cases; 71 % of malignant and 46 % of benign nodules. PTC group showed the highest TSHr methylation rate (87 %), followed by 61 % in AUS, 44 % in B, and 30 % in FN (p = 0.016). TSHr methylation rate was significantly higher in PTC group when compared to B (p = 0.013) and FN-B (p = 0.004) groups; but not in FN-M (p = 0.115) or AUS (p = 0.096) groups. All 9 cases of papillary thyroid carcinoma with lymph node metastasis showed TSHr methylation. Positive predictive value, negative predictive value, sensitivity and specificity of TSHr methylation in determination of malignancy were calculated as 60, 66, 71 and 54 %, respectively. CONCLUSION: The eminent ratio of TSHr methylation in well-differentiated thyroid carcinoma against benign thyroidal nodules adduced that TSHr methylation status can be utilized as a tumor marker for well-differentiated thyroid cancer; however, it has a limited value. The determination of methylation status of TSHr gene had no efficiency on decision of the malignant potential for the nodules which are cytologically classified as atypia of undetermined significance. BioMed Central 2015-10-30 /pmc/articles/PMC4628362/ /pubmed/26519197 http://dx.doi.org/10.1186/s12885-015-1861-1 Text en © Kartal et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kartal, Kinyas
Onder, Sevgen
Kosemehmetoglu, Kemal
Kilickap, Sadettin
Tezel, Yesim Gaye
Kaynaroglu, Volkan
Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material
title Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material
title_full Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material
title_fullStr Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material
title_full_unstemmed Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material
title_short Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material
title_sort methylation status of tshr in well-differentiated thyroid cancer by using cytologic material
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628362/
https://www.ncbi.nlm.nih.gov/pubmed/26519197
http://dx.doi.org/10.1186/s12885-015-1861-1
work_keys_str_mv AT kartalkinyas methylationstatusoftshrinwelldifferentiatedthyroidcancerbyusingcytologicmaterial
AT ondersevgen methylationstatusoftshrinwelldifferentiatedthyroidcancerbyusingcytologicmaterial
AT kosemehmetoglukemal methylationstatusoftshrinwelldifferentiatedthyroidcancerbyusingcytologicmaterial
AT kilickapsadettin methylationstatusoftshrinwelldifferentiatedthyroidcancerbyusingcytologicmaterial
AT tezelyesimgaye methylationstatusoftshrinwelldifferentiatedthyroidcancerbyusingcytologicmaterial
AT kaynarogluvolkan methylationstatusoftshrinwelldifferentiatedthyroidcancerbyusingcytologicmaterial